Halofuginone

Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000. It is widely used in veterinary medicine as an antiprotozoal agent to treat and prevent parasitic infections like coccidiosis in poultry and cryptosporidiosis in calves. Its therapeutic use is listed as antiparasitics and antiprotozoals. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Halofuginonum, Halocur and Halofuginon. Its PubChem CID is 456390.

CAS No 55837-20-2
Molecular Formula C16H17BrClN3O3
Molecular Weight 414.7 g/mol
Synonyms 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one

Frequently Asked Questions